Program
fluticasone furoate
Also written as “GW685698X”, “FF/UMEC/VI” and “Fluticasone furoate”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 942 open or running | phase 4since Feb 14, 2007 | Feb 8, 2005 | Jan 26, 2027phase 3 · NCT05757102 |
| Novartis | 10 open or running | phase 3since Jan 17, 2011 | Jan 17, 2011 | none ahead |
| ORA | 10 open or running | phase 4since Feb 24, 2010 | Feb 24, 2010 | none ahead |
| Sandoz | 10 open or running | phase 3since Oct 15, 2025 | Oct 15, 2025 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since May 20, 2010.
- Mar 24, 2016Phase 4 study in AsthmaGlaxoSmithKline · NCT02730351 · 75 enrolled · United States, Canada
- Jul 15, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02837380 · 16 enrolled · China
- Aug 31, 2016Phase 4 study in AsthmaGlaxoSmithKline · NCT02889809 · 477 enrolled · United States, Argentina, Poland and more
- Nov 30, 2017Phase 4 study in AsthmaGlaxoSmithKline · NCT03363191
- Dec 1, 2017Phase 3 study in AsthmaGlaxoSmithKline · NCT03376932
- Feb 2, 2018Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03467425 · 3,109 enrolled · Germany, Netherlands, Spain and more
- Mar 15, 20183 phase 4 studies in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03474081, NCT03478696, NCT03478683
- May 13, 2019Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03949842 · United States
- Jun 2, 2021Phase 3 study in AsthmaGlaxoSmithKline · NCT04937387 · 359 enrolled · China
- Jun 6, 2021Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT04923347 · 229 enrolled · India
- Sep 7, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT05535972 · 463 enrolled · China
- Feb 24, 2023Phase 3 study in AsthmaGlaxoSmithKline · NCT05757102 · 138 enrolled · United States, Argentina, Australia and more
- Apr 15, 2024Phase 4 study in AsthmaGlaxoSmithKline · NCT06372496 · 1,358 enrolled · United States, Argentina, Australia and more
- Oct 15, 2025Sandoz’s first study: phase 3 study in RespiratoryNew to SandozSandoz · NCT07223294
Ahead
- Jan 26, 2027Primary completion: phase 3 study in AsthmaGlaxoSmithKline · NCT05757102
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
The newest 60 of 97 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07223294Respiratory | 3 | Withdrawn | Sandoz | Apr 21, 2026 | 0 |
| NCT06372496Asthma · United States, Argentina, Australia and more | 4 | Active, not recruiting | GlaxoSmithKline | Jul 28, 2025 | 1,358 |
| NCT05757102Asthma · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | Jan 26, 2027 | 138 |
| NCT05535972Pulmonary Disease, Chronic Obstructive · China | 4 | Completed | GlaxoSmithKline | Sep 25, 2023 | 463 |
| NCT04923347Pulmonary Disease, Chronic Obstructive · India | 4 | Completed | GlaxoSmithKline | Mar 14, 2024 | 229 |
| NCT04937387Asthma · China | 3 | Completed | GlaxoSmithKline | Aug 5, 2024 | 359 |
| NCT03949842Pulmonary Disease, Chronic Obstructive · United States | 4 | Withdrawn | GlaxoSmithKline | Nov 30, 2022 | 0 |
| NCT03478696Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany | 4 | Completed | GlaxoSmithKline | Mar 18, 2019 | 732 |
| NCT03478683Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany and more | 4 | Completed | GlaxoSmithKline | Mar 14, 2019 | 729 |
| NCT03474081Pulmonary Disease, Chronic Obstructive · United States, Poland, Russian Federation | 4 | Completed | GlaxoSmithKline | Jul 17, 2019 | 800 |
| NCT03467425Pulmonary Disease, Chronic Obstructive · Germany, Netherlands, Spain and more | 4 | Completed | GlaxoSmithKline | Oct 10, 2019 | 3,109 |
| NCT03376932Asthma | 3 | Withdrawn | GlaxoSmithKline | Feb 3, 2021 | 0 |
| NCT03363191Asthma | 4 | Withdrawn | GlaxoSmithKline | May 29, 2019 | 0 |
| NCT02889809Asthma · United States, Argentina, Poland and more | 4 | Completed | GlaxoSmithKline | Apr 9, 2021 | 477 |
| NCT02837380Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | GlaxoSmithKline | Nov 2016 | 16 |
| NCT02730351Asthma · United States, Canada | 4 | Completed | GlaxoSmithKline | Feb 3, 2017 | 75 |
| NCT02712047Asthma · New Zealand | 2 | Completed | GlaxoSmithKline | Feb 21, 2017 | 28 |
| NCT02666287Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | GlaxoSmithKline | Jun 3, 2016 | 48 |
| NCT02573870Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | GlaxoSmithKline | Jul 5, 2016 | 63 |
| NCT02502734Asthma · Denmark | 3 | Completed | GlaxoSmithKline | Dec 21, 2015 | 60 |
| NCT02483975Asthma · United States, South Africa | 3 | Completed | GlaxoSmithKline | Jun 20, 2016 | 111 |
| NCT02446418Asthma · France, Germany | 3 | Completed | GlaxoSmithKline | Jul 20, 2017 | 423 |
| NCT02164513Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Jul 17, 2017 | 10,355 |
| NCT02105974Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Germany and more | 3 | Completed | GlaxoSmithKline | Jul 8, 2015 | 1,621 |
| NCT02094937Asthma · Japan | 3 | Completed | GlaxoSmithKline | Aug 28, 2015 | 430 |
| NCT02064504Pulmonary Disease, Chronic Obstructive · Australia | 1 | Completed | GlaxoSmithKline | May 20, 2014 | 48 |
| NCT01962467Rhinitis · Australia | 1 | Completed | GlaxoSmithKline | Feb 27, 2014 | 30 |
| NCT01957150Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more | 4 | Completed | GlaxoSmithKline | Mar 26, 2018 | 283 |
| NCT01808339Asthma · Australia | 2 | Completed | GlaxoSmithKline | Mar 2014 | 28 |
| NCT01691547Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | GlaxoSmithKline | Mar 8, 2013 | 44 |
| NCT01686633Asthma · United States, Argentina, Chile and more | 3 | Completed | GlaxoSmithKline | Oct 1, 2013 | 1,040 |
| NCT01691885Pulmonary Disease, Chronic Obstructive · United Kingdom | 3 | Completed | GlaxoSmithKline | Jul 2014 | 45 |
| NCT01630135Rhinitis, Allergic, Perennial · Japan | 3 | Completed | GlaxoSmithKline | Aug 2012 | 261 |
| NCT01627327Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more | 3 | Completed | GlaxoSmithKline | Dec 1, 2012 | 623 |
| NCT01622231Rhinitis · Japan | 3 | Completed | GlaxoSmithKline | Nov 2012 | 61 |
| NCT01563029Asthma · United States, Bulgaria, Georgia and more | 2 | Completed | GlaxoSmithKline | Sep 24, 2014 | 597 |
| NCT01498679Asthma · China, Korea, Republic of, Philippines | 3 | Completed | GlaxoSmithKline | Jul 2013 | 311 |
| NCT01498653Asthma · China, Korea, Republic of, Philippines | 3 | Completed | GlaxoSmithKline | Feb 2013 | 313 |
| NCT01499446Asthma · Brazil, Bulgaria, Chile and more | 2 | Completed | GlaxoSmithKline | Mar 2004 | 669 |
| NCT01485445Asthma · Germany | 1 | Completed | GlaxoSmithKline | Mar 12, 2012 | 30 |
| NCT01436110Asthma · United States, Mexico, Netherlands and more | 3 | Completed | GlaxoSmithKline | Sep 2012 | 351 |
| NCT01436071Asthma · United States, Mexico, Peru and more | 3 | Completed | GlaxoSmithKline | Jun 2012 | 248 |
| NCT01435902Asthma | 3 | Withdrawn | GlaxoSmithKline | Aug 2012 | 0 |
| NCT01431950Asthma · United States, Argentina, Chile and more | 3 | Completed | GlaxoSmithKline | Oct 2012 | 238 |
| NCT01395888Pulmonary Disease, Chronic Obstructive · Argentina, France, Germany and more | 3 | Completed | GlaxoSmithKline | Aug 1, 2012 | 260 |
| NCT01342913Pulmonary Disease, Chronic Obstructive · Belgium, France, Germany and more | 3 | Completed | GlaxoSmithKline | Oct 1, 2011 | 528 |
| NCT01323634Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany and more | 3 | Completed | GlaxoSmithKline | Dec 14, 2011 | 519 |
| NCT01323621Pulmonary Disease, Chronic Obstructive · United States, Germany, Italy and more | 3 | Completed | GlaxoSmithKline | Jan 1, 2012 | 512 |
| NCT01313676Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Jul 15, 2015 | 16,568 |
| NCT01279057Rhinitis, Allergic, Seasonal · United States | 3 | Completed | Novartis | Feb 8, 2011 | 727 |
| NCT01244984Asthma · Japan | 3 | Completed | GlaxoSmithKline | Jan 2012 | 243 |
| NCT01332292Asthma · United States | 2 | Completed | GlaxoSmithKline | Jan 2011 | 27 |
| NCT01231464Rhinitis, Allergic, Perennial · China | 3 | Completed | GlaxoSmithKline | May 2010 | 365 |
| NCT01213849Asthma · United Kingdom | 1 | Completed | GlaxoSmithKline | Nov 25, 2010 | 24 |
| NCT01165138Asthma · United States, Germany, Japan and more | 3 | Completed | GlaxoSmithKline | Oct 1, 2011 | 612 |
| NCT01159912Asthma · United States, Belgium, Germany and more | 3 | Completed | GlaxoSmithKline | Jan 1, 2012 | 350 |
| NCT01299558Asthma · Australia | 1 | Completed | GlaxoSmithKline | Jul 15, 2010 | 16 |
| NCT01147848Asthma · United States, Argentina, Chile and more | 3 | Completed | GlaxoSmithKline | Jul 2011 | 810 |
| NCT01134042Asthma · United States, Germany, Japan and more | 3 | Completed | GlaxoSmithKline | Oct 2011 | 587 |
| NCT01128595Asthma · Australia, New Zealand, Sweden | 2 | Completed | GlaxoSmithKline | May 2011 | 27 |
How it is read
Names in the registry
- “GW685698X”, 16 entries
- “FF/UMEC/VI”, 9 entries
- “Fluticasone furoate”, 8 entries
- “FF”, 6 entries
- “Fluticasone Furoate”, 5 entries
Codes read as this program: GW685698.
Conditions, from the studies’ own filings
- Asthma, 44 studies
- Pulmonary Disease, Chronic Obstructive, 23 studies
- Rhinitis, Allergic, Perennial, 15 studies
- Rhinitis, Allergic, Seasonal, 9 studies
- Rhinitis, Allergic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.